GlassScriptPhysician profile
Mark Robertshaw
NPI 1396277265
$1,488.95
in general payments reported to CMS, 2019-2025
19 companies · $936 in 2025
The $936 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $181 · 2024: $372 · 2025: $936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,488.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $264.91 | 2023-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $247.49 | 2023-2025 | Fasenra, Airsupra, Breztri |
| Genzyme Corporation | $197.08 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.08 | 2023-2025 | Ofev, Jascayd |
| Baxter Healthcare | $92.10 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $84.03 | 2024-2025 | Tyvaso, Tyvaso |
| Insmed, INC. | $76.08 | 2023-2025 | Arikayce |
| Abbvie INC. | $50.68 | 2024-2025 | |
| Grifols USA, LLC | $49.93 | 2024-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $48.14 | 2025 | Yupelri |
| Philips North America LLC | $38.71 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Electromed, INC. | $37.64 | 2023-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $30.36 | 2023-2025 | Acthar |
| Gilead Sciences, INC. | $26.23 | 2024 | |
| Pulmonx Corporation | $26.01 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $24.28 | 2025 | Pocket Eeg Device |
| Inspire Medical Systems, INC. | $19.38 | 2023 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $18.68 | 2025 | Glassia |
| Amgen INC. | $14.14 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Robertshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.